Medicus Pharma is a clinical-stage biotech company developing two drug candidates with no commercial products or revenue. Medicus operates through two subsidiaries: SkinJect, which is developing D-MNA (a dissolvable microneedle patch that delivers the chemotherapy drug doxorubicin directly into basal cell carcinoma tumors), and Antev, which is developing Teverelix, an injectable GnRH antagonist for advanced prostate cancer patients with high cardiovascular risk and for prevention of recurrent acute urinary retention in men with enlarged prostates. D-MNA completed a Phase 2 trial showing 73% clinical clearance at the 200µg dose, and the company believes results support an end-of-Phase-2 FDA meeting; a second Phase 2 study is ongoing in the UAE. Teverelix has FDA-cleared Phase 2b designs for both indications. Medicus's business model centers on advancing assets to Phase 2 proof-of-concept, then out-licensing or partnering with larger pharma companies for late-stage development and commercialization — limiting capital needs but also capping upside. Medicus acquired Antev for roughly $3M cash plus stock, with up to ~$65M in contingent milestone payments, consistent with its capital-efficient acquire-and-advance approach. SkinJect's technology is licensed from the University of Pittsburgh with a 3% royalty on net sales, and Teverelix is in-licensed from LifeArc at a 2% royalty. The company funds operations through equity and debt financing and explicitly acknowledges going-concern risk.